FAS and ovarian cancer: Remarkably, while incorporation of an ethyl secondary hydroxyl group to (±)-UB006 did not display a higher inhibitory effect on FAS activity, it significantly increased the in vitro antitumor effects against the ovarian cancer cell line, OVCAR3.